From March 13 to 15, 2026, the 2026 Academic Annual Conference on Swine Production of the Swine Branch of Guangxi Association of Animal Science and Veterinary Medicine was grandly opened in Nanning, Guangxi province. Under the theme "Health, Cost, Intelligence, Environmental Protection," the conference brought together over 1,200 experts, scholars, leading enterprise representatives, large-scale pig farm owners, and industry chain professionals from across China to explore industry pain points and new development pathways. As a gold sponsor of the event, VJTBio was invited to attend. The company not only invited industry experts to deliver major technical presentations on batch farrowing production but also seized the opportunity to host the Guangxi regional launch ceremony for its National Class I new veterinary drug VJT101, injecting vitality into the high-quality development of Guangxi's swine industry with groundbreaking innovative technology.

The opening ceremony was presided over by Xu Dianxin, Senior Chairman of the Swine Branch of Guangxi Association of Animal Science and Veterinary Medicine.  Luo Tingrong, Chairman of the Guangxi Association of Animal Science and Veterinary Medicine, emphasized in his address that the swine industry must adhere to technological innovation, derive benefits from "new quality productivity," while promoting green development models and strengthening disease prevention and control systems. An official from the Animal Husbandry and Veterinary Division of the Guangxi Department of Agriculture and Rural Affairs also stressed the need to shift the focus of the swine industry toward improving quality and efficiency, and to drive its transformation and upgrading in the directions of high efficiency, intelligence, and environmental protection. Against this industry backdrop, batch farrowing production has become a core lever for reducing costs, improving efficiency, and enhancing risk resilience in the swine industry. VJTBio, with its years of accumulated innovative technologies and products for batch farrowing production, made a timely appearance that precisely aligned with the development needs of Guangxi's swine industry.

The academic report session of the conference was rich and diverse, with several renowned domestic experts sharing cutting-edge technologies. Among them, Professor Zhang Shouquan from the College of Animal Science, South China Agricultural University, delivered a keynote report titled "2026 - The First Year of 4-Week Batch Production in China's Swine Industry." He deeply analyzed the core value of the 4-week batch production model from an industry development perspective, clarifying its significant advantages in disease prevention and reproductive efficiency improvement. He also provided technical evidence for the critical role of VJTBio's recombinant protein drugs in helping pig farms stably implement the 4-week batch production model, achieving cost reduction and efficiency gains, and charting a clear direction for technological upgrading for industry practitioners.

Zhao Changsong, Senior Technical Service Specialist at VJTBio, also shared insights in a presentation titled "VJTBio Empowers Batch Farrowing Production." He directly addressed current industry pain points in batch farrowing production, such as improper management of estrus cycles in replacement gilts and first-litter sow syndrome. Based on the actual farming conditions in Guangxi, he proposed targeted solutions, providing replicable and easily implementable practical pathways for the efficient implementation of batch farrowing production in local pig farms.

During the conference, VJTBio reached a brand highlight moment - the grand launch ceremony for the Guangxi regional launch of the National Class I new veterinary drug VJT101. Xu Dianxin, Chairman of the Guangxi Swine Branch, together with other professors, Li Qiping, General Manager of VJTBio's Guangxi regional partner, Huang Zheng, Marketing Director of VJTBio, and Cheng Shiwen, Technical Director of VJTBio, jointly took the stage to inaugurate the launch, marking the official entry of this technology, developed over nine years, into the Guangxi market. As a National Class I new veterinary drug developed leveraging the company's advantages in recombinant protein hormone innovation, VJT101 precisely addresses the production efficiency challenges in batch farrowing production, filling a gap in the field of high-efficiency reproductive technology in Guangxi. It effectively helps regional pig farms meet their core needs for precise insemination, high farrowing efficiency, and cost reduction, providing a reliable reproductive regulation solution for large-scale farming.

VJTBio's appearance at the 2026 Guangxi Swine Academic Annual Conference was not only a powerful demonstration of the company's technological and product strength but also an important strategic practice in integrating industry resources and empowering regional industrial development. From inviting renowned experts to share cutting-edge technologies to launching a blockbuster new product in Guangxi, VJTBio closely aligned with the conference theme of "Health, Cost, Intelligence, Environmental Protection," building a bridge for technical exchange and resource sharing for Guangxi's swine industry and facilitating the regional adoption of advanced batch farrowing production technologies.

Looking ahead, VJTBio will continue to deepen its collaboration with local partners in Guangxi, precisely deploying advanced batch farrowing production technologies and high-quality products to address local farming pain points, and helping Guangxi's swine industry advance toward improved quality, efficiency, and high-quality development.